Clinical Research Directory
Browse clinical research sites, groups, and studies.
Pharmacogenetic Testing at Community Pharmacy
Sponsor: Chantal Csajka
Summary
The purpose of this study is to assess the clinical impact of reducing treatment failure rates after using genetic information targeting CYP2C19 in validating escitalopram prescription. 5 pharmacies in the canton of Vaud (Lausanne, Switzerland) will participate in the study. The study will also explored the ability to perform the test in community pharmacy, physician and pharmacist approval of prescription changes, patient acceptance of the test and dose changes, the economic impact of the test, the association between genetic polymorphisms and therapeutic failures and the degree of satisfaction, barriers and facilitators by stakeholders.
Official title: Randomised Controlled Study of the Efficacy and Acceptability of a Pharmacogenetic Test in the Management of Patients Treated With Escitalopram.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
270
Start Date
2025-08-15
Completion Date
2027-08-14
Last Updated
2025-06-05
Healthy Volunteers
No
Conditions
Interventions
Prescription of escitalopram using pharmacogenetic testing
Adjustment of escitalopram treatment according to pharmacogenetic results obtained by genetic testing for cytochrome CYP 2C19 (alleles \*2, \*3 and \*17)